Parecoxib sodium, a parenteral cyclooxygenase 2 selective inhibitor, improves morphine analgesia and is opioid-sparing following total hip arthroplasty

Anesthesiology

Volumn 98, Issue 4, 2003, Pages 950-956

  Malan Jr , T Philip ^a   Marsh, Gregory ^b   Hakki, Sam I ^c   Grossman, Evie ^d   Traylor, Louise ^d   Hubbard, Richard C ^d  

^a UNIVERSITY OF ARIZONA   (United States)

^b St Joseph Hospital Tacoma   (United States)

^c Bay Pines VA Medical Center   (United States)

^d PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MORPHINE; OPIATE; PARECOXIB;

ADULT; AGED; ANALGESIA; ANEMIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; GLOBAL EVALUATION RATING; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PAIN ASSESSMENT; PATIENT CONTROLLED ANALGESIA; POSTOPERATIVE ANALGESIA; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; TACHYCARDIA; TOTAL HIP PROSTHESIS; VERTIGO; VOMITING;

AGED; ANALGESIA, PATIENT-CONTROLLED; ANALGESICS, OPIOID; ARTHROPLASTY, REPLACEMENT, HIP; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; ISOENZYMES; ISOXAZOLES; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MORPHINE; PAIN MEASUREMENT; PAIN, POSTOPERATIVE; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 0037382163     PISSN: 00033022     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000542-200304000-00023     Document Type: Article

References (46)

1. Kehlet H, Rung GW, Callesen T: Postoperative opioid analgesia: time for a reconsideration? J Clin Anesth 1996; 8:441-5
2. Mulroy MF: Monitoring opioids. Reg Anesth 1996; 21:89-93
3. Wheeler M, Oderda G, Ashburn M, Lipman A: Adverse events associated with postoperative opioid analgesia: A systematic review. J Pain 2002; 3:159-80
4. Kehlet H, Dahl JB: The value of "multimodal" or "balanced analgesia" in postoperative pain treatment. Anesth Analg 1993; 77:1048-56
5. Blackburn A, Stevens JD, Wheatley RG, Madej TH, Hunter D: Balanced analgesia with intravenous ketorolac and patient-controlled morphine following lower abdominal surgery. J Clin Anesth 1995; 7:103-8
6. Burns JW, Aitken HA, Bullingham RE, McArdle CS, Kenny GN: Double-blind comparison of the morphine sparing effect of continuous and intermittent i.m. administration of ketorolac. Br J Anaesth 1991; 67:235-8
7. Fogarty DJ, O'Hanlon JJ, Milligan KR: Intramuscular ketorolac following total hip replacement with spinal anaesthesia and intrathecal morphine. Acta Anaesthesiol Scand 1995; 39:191-4
8. Gillies GW, Kenny GN, Bullingham RE, McArdle CS: The morphine sparing effect of ketorolac tromethamine: A study of a new, parenteral nonsteroidal anti-inflammatory agent after abdominal surgery. Anaesthesia 1987; 42:727-31
9. Kenny GN, McArdle CS, Aitken HA: Parenteral ketorolac: Opiate-sparing effect and lack of cardiorespiratory depression in the perioperative patient. Phannacotherapy 1990; 10:127S-31S
10. Moffat AC, Kenny GN, Prentice JW: Postoperative nefopam and diclofenac: Evaluation of their morphine-sparing effect after upper abdominal surgery. Anaesthesia 1990; 45:302-5
11. Olofsson CI, Legeby MH, Nygards EB, Ostman KM: Diclofenac in the treatment of pain after caesarean delivery: An opioid-saving strategy. Eur J Obstet Gynecol Reprod Biol 2000; 88:143-6
12. Vane JR, Botting J: Overview: Mechanisms of action of anti-inflammatory drugs. Improved Nonsteroidal Anti-intlammatory Drugs: COX-2 Enzyme Inhibitors. Edited by Vane JR, Botting J, Botting R. Boston, Kluwer Academic Publishers, 1996, pp 1-27
13. Borda IT, Koff R: NSAIDs: A profile of adverse effects. Philadelphia, Hanley and Belfus, 1995
14. Cheng J-C, Siegel L, Katari B, Traynoff S, Ro J: Nonsteroidal anti-inflammatory drugs and aspirin: A comparison of the antiplatelet effect. Am J Ther 1997; 4:62-5
15. Feldman H, Kinman J, Berlin J, Hennessy S, Kimmel S, Farrar J, Carson J, Strom BL: Parenteral ketorolac: The risk of acute renal failure. Ann Intern Med 1997; 126:193-9
16. Singh G, Rosen Ramey D: NSAID induced gastrointestinal complications: The ARAMIS perspective 1997. Arthritis, Rheumatism, and Aging Medical Information System. J Rheumatol 1998; 51(suppl):8-16
17. Gierse JK, Hauser SD, Creely DP, Koboldt C, Rangwala SH, Isaksori PC, Seibert K: Expression and selective inhibition of the constitutive and inducible forms of human cyclooxygenase. Biochem J 1995; 305:479-84
18. Gierse JK, Koboldt CM, Walker MC, Seibert K, Isakson PC: Kinetic basis for selective inhibition of cyclooxygenases. Biochem J 1999; 339:607-14
19. Greenberg H, Gottesdiener K, Huntington M, Wong P, Larson P, Wildonger L, Gillen L, Dorval E, Waldman S: A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effect of low-dose aspirin in healthy volunteers. J Clin Pharmacol 2000; 40:1509-15
20. Leese PT, Hubbard RC, Karim A, Isakson PC, Yu SS, Geis GS: Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: A randomized, controlled trial. J Clin Pharmacol 2000; 40:124-32
21. Leese P, Talwalker S, Recker D, Kent J: Valdecoxib, a novel COX-2 specific inhibitor, does not impair platelet function in healthy adults: Results of a randomized controlled trial. Am J Emerg Med 2002; 20:275-81
22. Bombardier C, Laine L, Reicin AS, Shapiro A, Burgos-Vargas R, Davis B, Ferraz M, Hawkey C, Hochberg M, Kvien TK, Schnitzer TJ: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343:1520-8
23. Kivitz AJ, Eisen G, Zhao WW, Bevirt T, Recker D: The COX-2 specific inhibitor valdecoxib is as effective as naproxen in treating symptomatic osteoarthritis of the knee and demonstrates reduced gastrointestinal ulceration. J Family Prac 2002; 51:530-7
24. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS: Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284:1247-55
25. Reuben SS, Connelly NR: Postoperative analgesic effects of celecoxib or rofecoxib after spinal fusion surgery. Anesth Analg 2000; 91:1221-5
26. Reuben SS, Connelly NR, Lurie S, Klatt M, Gibson CS: Dose-response of ketorolac as an adjunct to patient-controlled analgesia morphine in patients after spinal fusion surgery. Anesth Analg 1998; 87:98-102
27. Gillis JC, Brogden RN: Ketorolac: A reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic use in pain management. Drugs 1997; 53:139-88
28. Spowart K, Greer IA, McLaren M, Lloyd J, Bullingham RE, Forbes CD: Haemostatic effects of ketorolac with and without concomitant heparin in normal volunteers. Thromb Haemost 1988; 60:382-6
29. Strom BL, Berlin JA, Kinman JL, Spitz PW, Hennessy S, Feldman H, Kimmel S, Carson JL: Parenteral ketorolac and risk of gastrointestinal and operative site bleeding: A postmarketing surveillance study. JAMA 1996; 275:376-82
30. Talley JJ, Brown DL, Carter JS, Graneto MJ, Koboldt CM, Masferrer JL, Perkins WE, Rogers RS, Shaffer AF, Zhang YY, Zweifel BS, Seibert K: 4-[5-Methyl-3-phenylisoxazol4-yl]-benzenesulfonamide, valdecoxib: A potent and selective inhibitor of COX-2. J Med Chem 2000; 43:775-7
31. Barton SF, Langeland FF, Snabes MC, LeComte DL, Kuss M, Dhadda SS, Talwalker S: Efficacy and safety of intravenous parecoxib sodium in relieving acute postoperative pain following laparotomy surgery. ANESTHESIOLOGY 2002; 97:306-14
32. Daniels S, Grossman E, Kuss M, Talwalker S, Hubbard RC: A double-blind, randomized comparison of intramuscularly and intravenously administered parecoxib sodium versus ketorolac and placebo in a post-oral surgery pain model. Clin Ther 2001; 23:1018-31
33. Desjardins PJ, Grossman E, Kuss M, Talwalker S, Dhadda SS, Baum D, Hubbard RC: The injectable cyclooxygenase-2-specific inhibitor parecoxib sodium has analgesic efficacy when administered preoperatively. Anesth Analg 2001; 93:721-7
34. Rasmussen GL, Steckner K, Hogue C, Kuss M, Torri S, Talwalker S, Hubbard RC: Intravenous parecoxib sodium for acute pain after postorthopedic knee surgery. Am J Orthopedics 2002; 31:334-43
35. Noveck RJ, Laurent A, Kuss M, Talwalker S, Hubbard RC: The COX-2 specific inhibitor, parecoxib sodium, does not impair platelet function in healthy elderly and nonelderly subjects: Two randomized, controlled trials. Clin Drug Invest 2001; 21:465-76
36. Harris S, Kuss M, Hubbard RC, Goldstein JL: Upper gastrointestinal tolerability evaluation of parecoxib sodium, a new parenteral COX-2 specific inhibitor, as compared to ketorolac, naproxen or placebo. Clin Ther 2001; 23:1422-8
37. Stoltz R, Harris S, Kuss M, LeComte DL, Talwalker S, Pan S, Hubbard RC: Upper gastrointestinal safety of parecoxib sodium in the elderly. Am J Gastroenterol 2002; 97:65-71
38. Delbos A, Boccard E: The morphine-sparing effect of propacetamol in orthopedic postoperative pain. J Pain Symptom Manag 1995; 10:279-86
39. Miller R: Survival Analyses. New York, John Wiley & Sons, 1998
40. Simon R, Lee YJ: Nonparametric confidence limits for survival probabilities and median survival time. Cancer Treat Rep 1982; 66:37-42.
41. Tang J, Li S, White P, Chen X, Wender RH, Quon R, Sloninsky A, Naruse R, Kariger R, Webb T, Norel E: Effect of parecoxib, a novel intravenous cyclooxygenase type-2 inhibitor, on the postoperative opioid requirement and quality of pain control. ANESTHESIOLOGY 2002; 96:1305-9
42. Hubbard RC, Naumann T, Traylor L, Dhadda SS: Parecoxib sodium demonstrates opioid-sparing effects in patients undergoing total knee arthroplasty surgery under spinal anaesthesia. Br J Anaesth 2002; 90:166-72
43. Mukherjee D, Nissen SE, Topol EJ: Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 286:954-9
44. Joint Commission on Accreditation of Healthcare Organizations: New clinical practice guidelines. Jt Comm Perspect 1999; 19:6-8
45. Choiniere M, Rittenhouse B, Perreault S, Chartrand D, Rousseau P, Smith B, Pepler C: Efficacy and costs of patient-controlled analgesia versus regularly administered intramuscular opioid therapy. ANESTHESIOLOGY 1998; 89:1377-88
46. Smythe M, Loughlinm K, Schad RF, Lucarroti RL: Patient-controlled analgesia versus intramuscular analgesic therapy. Am J Hosp Pharm 1994; 51:1433-40